CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic s...
Phase 1, Phase 2
Pozuelo de Alarcón, Madrid, Spain and 33 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed th...
Phase 1
Madrid, Spain and 33 other locations
or young adults with a certain kind of blood cancer (FLT3-ITD AML) might be able to join this study if it has come back after remission or i...
Phase 1, Phase 2
Madrid, Spain and 26 other locations
\[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse w...
Phase 3
Madrid, Spain and 85 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Madrid, Spain and 160 other locations
will be evaluated in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has ...
Phase 1, Phase 2
Madrid, Spain and 55 other locations
in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who ar...
Phase 1, Phase 2
Madrid, Spain and 33 other locations
when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progr...
Phase 2
Madrid, Spain and 40 other locations
with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitr...
Phase 1, Phase 2
Madrid, Spain and 48 other locations
to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML) with a mutation ...
Phase 3
Madrid, Spain and 169 other locations
Clinical trials
Research sites
Resources
Legal